A previous study showed that combining HMAs with the CAG (cytarabine, aclarubicin and G-CSF) regimen was well tolerated and improved prognosis in elderly patients with high-risk AML (17, 18). This evidence concerns the gene CSF3 and acute myeloid leukemia.